TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›MTVA›Financials
Annual statements · SEC XBRL · FY2016 – FY2025

MetaVia Inc. (MTVA) financials

Income statement

MetaVia Inc. (MTVA) income statement, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$14.7M-$33.1M-$15.5M-$20.2M-$29.7M-$15.3M-$19.6M-$15.9M-$28.8M-$13.7M
Net income-$14.6M-$33.4M-$15.5M-$21.3M-$29.7M-$15.3M-$14.0M-$12.5M-$27.6M-$13.0M
EPS (diluted)-$2.57-$3.23-$3.65-$4.08-$1.83-$19.81-$43.42-$2.46-$39.13-$7.35

Cash flow

MetaVia Inc. (MTVA) cash flow, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$11.0M-$26.9M-$14.5M-$7.04M-$10.8M-$15.1M-$11.7M-$10.8M-$24.7M-$15.7M
Capital expenditures——$3.00K$214K$4.00K$3.00K—$50.0K$8.00K$2.00K
Free cash flow——-$14.5M-$7.25M-$10.8M-$15.1M—-$10.8M-$24.7M-$15.7M

Balance sheet

MetaVia Inc. (MTVA) balance sheet, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$24.0M$18.5M$2.85M$13.9M$10.1M$16.4M$33.4M$22.4M$16.0M$10.3M
Total assets$24.8M$19.0M$3.82M$14.5M$11.0M$16.8M$33.5M$22.8M$16.3M$11.1M
Total liabilities$4.12M$15.1M$360K$2.18M$3.77M$2.20M$11.8M$6.10M$8.33M$5.79M
Shareholders' equity$20.6M$25.0K-$13.3M$12.3M$7.20M$14.6M$21.8M$16.7M$7.93M$5.33M
Retained earnings-$27.1M-$60.5M-$15.6M-$36.9M-$66.5M-$81.8M-$95.8M-$108M-$136M-$149M
Shares (wtd avg diluted)9.27M10.6M5.17M15.6M16.2M771K322K5.07M705K1.77M

Every figure is extracted from MetaVia Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is MetaVia Inc.'s free cash flow?
-$15.7M in FY2025 (operating cash flow -$15.7M minus $2.00K of capital expenditures), from the SEC cash-flow statement.
Does MTVA pay a dividend?
MetaVia Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full MTVA analysis — verdict, score & filings →Is MTVA a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.